These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28836572)

  • 21. Association of the Endothelial Nitric Oxide Synthase Gene T786C Polymorphism with In-Stent Restenosis in Chinese Han Patients with Coronary Artery Disease Treated with Drug-Eluting Stent.
    Zeng WP; Zhang R; Li R; Luo JF; Hu XF
    PLoS One; 2017; 12(1):e0170964. PubMed ID: 28129392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study.
    Basavarajaiah S; Naganuma T; Latib A; Sticchi A; Ciconte G; Panoulas V; Chieffo A; Montorfano M; Carlino M; Colombo A
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):522-528. PubMed ID: 26715370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between uric acid to albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.
    Liu W; Ding K; Bao J; Hu Y; Gui Y; Ye L; Wang L
    Coron Artery Dis; 2023 Dec; 34(8):589-594. PubMed ID: 37855441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-Fasting Hypertriglyceridemia as an Independent Risk Factor for Coronary In-Stent Restenosis after Primary Bare Metal Stent Implantation in Patients with Coronary Artery Disease.
    Yoshimura M; Umemoto S; Kawano R; Hiromoto M; Yamada M; Fujimura T; Tanaka M; Nao T; Miura T; Yano M
    Int Heart J; 2021; 62(5):970-979. PubMed ID: 34588411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Independent predictors of in-stent restenosis after drug-eluting stent implantation for ostial right coronary artery lesions.
    Watanabe Y; Takagi K; Naganuma T; Kawamoto H; Fujino Y; Ishiguro H; Tahara S; Kurita N; Hosawa K; Nakamura S; Nakamura S
    Int J Cardiol; 2017 Aug; 240():108-113. PubMed ID: 28476515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.
    Rittger H; Wöhrle J; Brachmann J; Hohenforst-Schmidt W; Schlundt C; Lonke S; von Cranach M; Markovic S; Achenbach S; Waliszewski M
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):529-534. PubMed ID: 26893095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease.
    Gabbasov Z; Kozlov S; Melnikov I; Byazrova S; Saburova O; Prokofieva L; Caprnda M; Curilla E; Gaspar L; Rodrigo L; Kruzliak P; Smirnov V
    Clin Appl Thromb Hemost; 2018 Nov; 24(8):1308-1314. PubMed ID: 29716394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9.
    Katsaros KM; Kastl SP; Zorn G; Maurer G; Wojta J; Huber K; Christ G; Speidl WS
    JACC Cardiovasc Interv; 2010 Jan; 3(1):90-7. PubMed ID: 20129576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean DES ISR multicenter registry study [KISS]).
    Ko YG; Kim JS; Kim BK; Choi D; Hong MK; Jeon DW; Yang JY; Ahn YK; Jeong MH; Yu CW; Yun KH; Lim DS; Jang Y;
    Am J Cardiol; 2012 Mar; 109(5):607-13. PubMed ID: 22172241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]).
    Alfonso F; Pérez-Vizcayno MJ; Dutary J; Zueco J; Cequier A; García-Touchard A; Martí V; Lozano I; Angel J; Hernández JM; López-Mínguez JR; Melgares R; Moreno R; Seidelberger B; Fernández C; Hernandez R;
    JACC Cardiovasc Interv; 2012 Jul; 5(7):728-37. PubMed ID: 22814777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
    Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
    J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study.
    Zhang L; Wang Y; Zhang Z; Liang H; Wu L; Ni L; Gao G; Yang D; Zhao H; Xiao J
    BMC Cardiovasc Disord; 2021 Sep; 21(1):438. PubMed ID: 34525967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of coronary collateral circulation on angiographic in-stent restenosis in patients with stable coronary artery disease and chronic total occlusion.
    Yang ZK; Shen Y; Hu J; Zhang Q; Ding FH; Zhang RY; Lu L; Shen WF
    Int J Cardiol; 2017 Jan; 227():485-489. PubMed ID: 27836292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
    Habara S; Iwabuchi M; Inoue N; Nakamura S; Asano R; Nanto S; Hayashi Y; Shiode N; Saito S; Ikari Y; Kimura T; Hosokawa J; Nakamura M; Kotani J; Kozuma K; Mitsudo K
    Am Heart J; 2013 Sep; 166(3):527-33. PubMed ID: 24016503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atherogenic Index of Plasma and the Risk of In-Stent Restenosis in Patients with Acute Coronary Syndrome beyond the Traditional Risk Factors.
    Zhu Y; Chen M; Liu K; Gao A; Kong X; Liu Y; Han H; Li H; Zhu H; Zhang J; Zhao Y
    J Atheroscler Thromb; 2022 Aug; 29(8):1226-1235. PubMed ID: 34497172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged double antiplatelet therapy in a cohort of "de novo" diabetic patients treated with drug-eluting stent implantation.
    Mollichelli N; Morici N; Ambrogi F; Latib A; Boracchi P; Godino C; Ferri L; Ielasi A; Chieffo A; Montorfano M; Colombo A
    Am J Cardiol; 2010 May; 105(10):1395-401. PubMed ID: 20451684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.
    Katsaros KM; Kastl SP; Krychtiuk KA; Hutter R; Zorn G; Maurer G; Huber K; Wojta J; Christ G; Speidl WS
    EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.